The 6 drugs with prices under congressional investigation

The House Oversight Committee is holding hearings Sept. 30 and Oct. 1 for drugmaker CEOs to testify about pricing practices, according to STAT.

The hearings come as part of an 18-month investigation first led by the late Rep. Elijah Cummings, D-Md., in 2019. 

Below are the six drugs the committee included in its probe, according to STAT:

  1. Revlimid, a multiple myeloma drug manufactured by Bristol Myers Squibb

  2. Copaxone, a multiple sclerosis drug manufactured by Teva

  3. Enbrel, an autoimmune disease drug manufactured by Amgen

  4. Sensipar, a secondary hyperparathyroidism drug manufactured by Amgen

  5. H.P. Acthar, hormone gel manufactured by Mallinckrodt

  6. Gleevec, a chemotherapy drug manufactured by Novartis

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars